20-[18F]fluoroarachidonic acid: Tissue biodistribution and incorporation into phospholipids

Fumi Nagatsugi, Junji Hokazono, Shigeki Sasaki, Minoru Maeda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The in vivo behavior of 20-[18F]fluoroarachidonic acid (18F-FAA) was investigated to evaluate its potential use as a radiotracer for studying the regional brain and heart lipid metabolism by positron emission tomography (PET). Tissue biodistribution studies in rats have revealed that 18F-FAA has a high uptake in the liver and lung, thus probably reflecting the metabolism, and is accompanied by both low in vivo defluorination and low blood levels. At 30 min postinjection, the uptake in the brain and heart reached values of 0.26 ± 0.02 and 1.22 ± 0.58% dose/g, respectively, with ratios to the blood radioactivity of 1.04 and 4.88, respectively. Lipid extraction at 30 min postinjection showed that 39% of the brain radioactivity was in the organic phase whereas the organic phase from heart tissue contained 73% of the total radioactivity. A TLC analysis demonstrated that 18F-FAA was mainly bound to phospholipids in the brain and heart tissue as expected. Based on the findings of this study, the utility of 18F-FAA as an in vivo tracer for cerebral phospholipid studies appears to be limited because of its relatively high radioactivity in the aqueous brain fraction. However, our findings do suggest that this agent might be useful as a tool for studies of cardiac phospholipid turnover, even though it demonstrated a poor heart-to-lung and heart-to-liver contrast.

Original languageEnglish
Pages (from-to)1316-1321
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 1996

Fingerprint

Phospholipids
Radioactivity
Brain
Lung
Liver
Lipid Metabolism
Positron-Emission Tomography
20-fluoroarachidonic acid
Lipids

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

20-[18F]fluoroarachidonic acid : Tissue biodistribution and incorporation into phospholipids. / Nagatsugi, Fumi; Hokazono, Junji; Sasaki, Shigeki; Maeda, Minoru.

In: Biological and Pharmaceutical Bulletin, Vol. 19, No. 10, 10.1996, p. 1316-1321.

Research output: Contribution to journalArticle

Nagatsugi, Fumi ; Hokazono, Junji ; Sasaki, Shigeki ; Maeda, Minoru. / 20-[18F]fluoroarachidonic acid : Tissue biodistribution and incorporation into phospholipids. In: Biological and Pharmaceutical Bulletin. 1996 ; Vol. 19, No. 10. pp. 1316-1321.
@article{ebed976c822e475b993ea7a779bce18d,
title = "20-[18F]fluoroarachidonic acid: Tissue biodistribution and incorporation into phospholipids",
abstract = "The in vivo behavior of 20-[18F]fluoroarachidonic acid (18F-FAA) was investigated to evaluate its potential use as a radiotracer for studying the regional brain and heart lipid metabolism by positron emission tomography (PET). Tissue biodistribution studies in rats have revealed that 18F-FAA has a high uptake in the liver and lung, thus probably reflecting the metabolism, and is accompanied by both low in vivo defluorination and low blood levels. At 30 min postinjection, the uptake in the brain and heart reached values of 0.26 ± 0.02 and 1.22 ± 0.58{\%} dose/g, respectively, with ratios to the blood radioactivity of 1.04 and 4.88, respectively. Lipid extraction at 30 min postinjection showed that 39{\%} of the brain radioactivity was in the organic phase whereas the organic phase from heart tissue contained 73{\%} of the total radioactivity. A TLC analysis demonstrated that 18F-FAA was mainly bound to phospholipids in the brain and heart tissue as expected. Based on the findings of this study, the utility of 18F-FAA as an in vivo tracer for cerebral phospholipid studies appears to be limited because of its relatively high radioactivity in the aqueous brain fraction. However, our findings do suggest that this agent might be useful as a tool for studies of cardiac phospholipid turnover, even though it demonstrated a poor heart-to-lung and heart-to-liver contrast.",
author = "Fumi Nagatsugi and Junji Hokazono and Shigeki Sasaki and Minoru Maeda",
year = "1996",
month = "10",
doi = "10.1248/bpb.19.1316",
language = "English",
volume = "19",
pages = "1316--1321",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

TY - JOUR

T1 - 20-[18F]fluoroarachidonic acid

T2 - Tissue biodistribution and incorporation into phospholipids

AU - Nagatsugi, Fumi

AU - Hokazono, Junji

AU - Sasaki, Shigeki

AU - Maeda, Minoru

PY - 1996/10

Y1 - 1996/10

N2 - The in vivo behavior of 20-[18F]fluoroarachidonic acid (18F-FAA) was investigated to evaluate its potential use as a radiotracer for studying the regional brain and heart lipid metabolism by positron emission tomography (PET). Tissue biodistribution studies in rats have revealed that 18F-FAA has a high uptake in the liver and lung, thus probably reflecting the metabolism, and is accompanied by both low in vivo defluorination and low blood levels. At 30 min postinjection, the uptake in the brain and heart reached values of 0.26 ± 0.02 and 1.22 ± 0.58% dose/g, respectively, with ratios to the blood radioactivity of 1.04 and 4.88, respectively. Lipid extraction at 30 min postinjection showed that 39% of the brain radioactivity was in the organic phase whereas the organic phase from heart tissue contained 73% of the total radioactivity. A TLC analysis demonstrated that 18F-FAA was mainly bound to phospholipids in the brain and heart tissue as expected. Based on the findings of this study, the utility of 18F-FAA as an in vivo tracer for cerebral phospholipid studies appears to be limited because of its relatively high radioactivity in the aqueous brain fraction. However, our findings do suggest that this agent might be useful as a tool for studies of cardiac phospholipid turnover, even though it demonstrated a poor heart-to-lung and heart-to-liver contrast.

AB - The in vivo behavior of 20-[18F]fluoroarachidonic acid (18F-FAA) was investigated to evaluate its potential use as a radiotracer for studying the regional brain and heart lipid metabolism by positron emission tomography (PET). Tissue biodistribution studies in rats have revealed that 18F-FAA has a high uptake in the liver and lung, thus probably reflecting the metabolism, and is accompanied by both low in vivo defluorination and low blood levels. At 30 min postinjection, the uptake in the brain and heart reached values of 0.26 ± 0.02 and 1.22 ± 0.58% dose/g, respectively, with ratios to the blood radioactivity of 1.04 and 4.88, respectively. Lipid extraction at 30 min postinjection showed that 39% of the brain radioactivity was in the organic phase whereas the organic phase from heart tissue contained 73% of the total radioactivity. A TLC analysis demonstrated that 18F-FAA was mainly bound to phospholipids in the brain and heart tissue as expected. Based on the findings of this study, the utility of 18F-FAA as an in vivo tracer for cerebral phospholipid studies appears to be limited because of its relatively high radioactivity in the aqueous brain fraction. However, our findings do suggest that this agent might be useful as a tool for studies of cardiac phospholipid turnover, even though it demonstrated a poor heart-to-lung and heart-to-liver contrast.

UR - http://www.scopus.com/inward/record.url?scp=0029658881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029658881&partnerID=8YFLogxK

U2 - 10.1248/bpb.19.1316

DO - 10.1248/bpb.19.1316

M3 - Article

C2 - 8913504

AN - SCOPUS:0029658881

VL - 19

SP - 1316

EP - 1321

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 10

ER -